证券时报·2026-02-09 15:21Core Viewpoint - The article discusses the recent stock market movements, particularly focusing on the significant rise in shares of Novo Nordisk and Eli Lilly, two major players in the weight loss drug market, amid legal challenges faced by Hims & Hers [1][6]. Group 1: Stock Market Movements - On February 9, U.S. stock indices opened lower, with the Dow Jones down 0.25%, S&P 500 down 0.33%, and Nasdaq down 0.49% [1]. - Major tech stocks showed mixed results, with Nvidia, Microsoft, Meta, and Broadcom slightly up, while Amazon fell nearly 3% and Apple dropped over 1% [2]. Group 2: Novo Nordisk and Eli Lilly Performance - Novo Nordisk's stock rose over 6%, while Eli Lilly's shares increased nearly 4% due to the legal actions against Hims & Hers [6]. - Novo Nordisk has filed a lawsuit against Hims & Hers for patent infringement related to the sale of a generic version of semaglutide, which is a key ingredient in its weight loss and diabetes drugs [6][8]. Group 3: Hims & Hers Legal Challenges - Hims & Hers' stock plummeted over 26% following the lawsuit, reflecting investor concerns about the potential risks associated with its competing product [6][7]. - The company has stated that the lawsuit is an attack on millions of Americans who rely on generic medications for personalized treatment [7]. Group 4: Regulatory Environment - The FDA has indicated it will restrict the use of GLP-1 active ingredients in unapproved compounded drugs, which has implications for Hims & Hers and similar companies [7][8]. - Analysts suggest that the FDA's actions are a positive signal for Novo Nordisk and Eli Lilly, as it may lead to a more regulated environment for compounded pharmaceuticals [8]. Group 5: Market Sentiment - Since peaking in June 2024, Novo Nordisk's market value has decreased by nearly two-thirds, with a cumulative drop of almost 50% over the past year [9].